% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{HoffmeisterWittmann:298967,
author = {P. Hoffmeister-Wittmann and P. Hoegen-Saßmannshausen$^*$
and L. Wicklein and F. Weykamp$^*$ and K. Seidensaal and C.
Springfeld and M. Dill$^*$ and T. Longerich and P.
Schirmacher and A. Mehrabi and R. M. Mathy and B. C. Köhler
and J. Debus$^*$ and K. Herfarth and J. Liermann},
title = {{S}tereotactic body radiotherapy with carbon ions as local
ablative treatment in patients with primary liver cancer.},
journal = {Radiation oncology},
volume = {20},
number = {1},
issn = {1748-717X},
address = {London},
publisher = {BioMed Central},
reportid = {DKFZ-2025-00396},
pages = {23},
year = {2025},
abstract = {Liver cancer is the third leading cause of cancer related
death due to treatment resistance and late onset of symptoms
(Rumgay in J Hepatol 77: 1598-1606, 2022). The role of
external beam radiotherapy (EBRT) in treatment of
unresectable liver cancer needs to be defined. The use of
particle therapy such as carbon ion radiation therapy (CIRT)
with high linear energy transfer (LET) could increase
efficacy of EBRT while limiting the toxic effects of
radiation on non-cancerous liver tissue. Promising effects
of CIRT have been described in several studies during the
past decades, mostly in Japan. To date, no standardized
treatment protocol has been established and European data on
CIRT for liver cancer is lacking. This retrospective
analysis aims to investigate efficacy and safety of
hypofractionated CIRT compared to photon-based stereotactic
body radiation (SBRT) in primary liver cancer.Thirty-six (n
= 36) and twenty (n = 20) patients with primary malignant
liver tumors were treated with hypofractionated CIRT (4
fractions) and photon-based SBRT, respectively, between 2011
and 2022 and were retrospectively evaluated for survival,
local control, and toxicity.Two-year local control rate
after CIRT was $92.3\%.$ Compared to photon- based SBRT,
CIRT scores with a significantly longer median distant
progression free survival (3.1 versus 0.9 years). In a
matched pair comparison of the two treatment regimens, the
CIRT cohort demonstrated both longer 2-year overall survival
$(100\%$ versus $59.6\%)$ and longer 2-year distant PFS
$(75.7\%$ versus $22.9\%).$ No significant impairment of
liver function was observed in either cohort.In this
retrospective analysis, patients who received CIRT presented
excellent local tumor control and had better oncologic
outcomes than patients who received photon-based SBRT. SBRT
with carbon ions is a promising local ablative treatment
option that needs further investigation in large prospective
trials.},
keywords = {Humans / Liver Neoplasms: radiotherapy / Radiosurgery:
adverse effects / Radiosurgery: methods / Retrospective
Studies / Heavy Ion Radiotherapy: adverse effects / Aged /
Male / Female / Middle Aged / Aged, 80 and over / Survival
Rate / Adult / Carcinoma, Hepatocellular: radiotherapy /
Carcinoma, Hepatocellular: mortality / Carcinoma,
Hepatocellular: pathology / Carbon ion radiotherapy (Other)
/ Cholangiocarcinoma (Other) / Hepatocellular carcinoma
(Other) / Hypofractionation (Other) / Local control (Other)
/ SBRT (Other)},
cin = {E050 / D500 / HD01},
ddc = {610},
cid = {I:(DE-He78)E050-20160331 / I:(DE-He78)D500-20160331 /
I:(DE-He78)HD01-20160331},
pnm = {315 - Bildgebung und Radioonkologie (POF4-315)},
pid = {G:(DE-HGF)POF4-315},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:39966902},
doi = {10.1186/s13014-025-02594-y},
url = {https://inrepo02.dkfz.de/record/298967},
}